Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Patients and methods The severity
2025-01-07

Patients and methods The severity of disease documented at each outpatient visit was graded according to the modified Osserman classification: grade I, focal disease (e.g. restricted to ocular muscles); grade II, generalised disease that is mild (IIa) or moderate (IIb); grade III, severe generali
-
br Introduction Myasthenia gravis MG is
2025-01-07

Introduction Myasthenia gravis (MG) is an autoimmune disease characterised by failure of transmission at the neuromuscular junction (NMJ). In 80–85% of myasthenia gravis patients, the disease is mediated by antibodies to the nicotinic Blood sugar control receptor (AChR; (Lindstrom et al., 1976).
-
br ACh and ER tests hereafter Spasm provocation tests have
2025-01-07

ACh and ER tests hereafter Spasm provocation tests have self-limitations to document coronary artery spasm during daily life. In the past reports, ST elevation was reproducible in some patients with variant pomada retin a 0.1 by the administration of ACh or ER. However, we now employ the ER and
-
br Conclusions br Conflicts of interest br
2025-01-07

Conclusions Conflicts of interest Acknowledgements This work was supported by Ege University Research Fund [BAP, 14-ECZ-030, 2016]. Introduction The interest in the effects of endocrine disrupting chemicals (EDCs) in the aquatic environment continues to increase over the past decade, sp
-
The synthetic route to M developed by Rice was utilized
2025-01-07

The synthetic route to M100907 developed by Rice was utilized, however, the chiral resolution was carried out at an earlier stage to provide the possibility of introducing different substituents onto the piperidinyl group. The conditions for this resolution were different from previously reported.
-
AZD0156 Loss of expression or functional activity
2025-01-06

Loss of expression or functional activity of cell adhesion is intricately related to advanced stages of tumour progression and invasiveness. Martin-Belmonte and Perez-Moreno recently mentioned that the deregulation of adhesion can alter tumourgenesis in the early stage. We have shown for the first t
-
In conclusion the partial sequencing and characterization of
2025-01-06

In conclusion, the partial sequencing and characterization of R. quelen cyp19a1b provides essential information about this gene and its presence in peripheral tissues outside of the central nervous system in a teleost. Furthermore, we covered sex differences in the effects of E2 on the cyp19a1b gene
-
EdU cell proliferation imaging We also explored the possibil
2025-01-06

We also explored the possibility that this PKC-θ activating protein could operate on the auto-phosphorylation process of the kinase, a specific event accompanying PKC activation [32]. The heated PKC-θ immunoprecipitate from metaphasic cells was then added to PKC-θ isolated both from interphasic or m
-
F is an orotomide a novel class of antifungals
2025-01-06

F901318 is an orotomide, a novel class of antifungals, which inhibits pyridine biosynthesis by blocking dihydroorotate dehydrogenase (URA1) activity [137]. Although this pathway is conserved in humans, human URA1 is only 20% identical to its fungal homolog and it is inhibited 2000-fold less effectiv
-
br Acknowledgments br Introduction Angiotensin II
2025-01-06

Acknowledgments Introduction Angiotensin II (AngII) is among the most potent vasoactive substances produced in humans. Its effects are numerous, from vasoconstriction to control of fluid and electrolytes balances. Many of the physiological and pathological effects of AngII are mediated by the
-
br Methodology In this paper mechanical properties of G
2025-01-04

Methodology In this paper, mechanical properties of G-actin are examined. To do so, three different external tensile loads are exerted to the protein. As illustrated in Fig. 1, Arp2/3 complex binds to the one sides of mother 22(R)-hydroxy Cholesterol and leads to the growth of a new daughter fil
-
Previous reports indicate that the expression of AChRs and t
2025-01-04

Previous reports indicate that the expression of AChRs and their clustering on myotubes are critical factors required to induce contacts on muscle fibers in a natural biological system [14], [15], [16], [17], [18], [19]. For instance, in NMJ development in the mouse, AChRs are pre-patterned at sites
-
To date the molecular responses of AChE
2025-01-04

To date, the molecular responses of AChE have been partially analyzed in its mRNA level or protein activity in aquatic animals. To understand the correlation between transcriptional change and activity of AChE, we conducted both experiments in B. koreanus. Generally, the Tyrosine kinase inhibition r
-
In the final set of experiments
2025-01-04

In the final set of experiments, the dependence of the reaction rate on viscosity was determined. The experimental protocol previously used to study the reaction of LOX with AA was used., Reactions of 5-LOX and AA were carried out at different relative viscosities in Tris buffer (25mM, pH 8.0) at 2
-
In the previous study we demonstrated the importance
2025-01-04

In the previous study, we demonstrated the importance of the mPFC postsynaptic 5-HT1A receptor in the sustained antidepressant effects, because a sustained antidepressant effect was obtained with intra-mPFC injection, but not systemic injection of 8-OH-DPAT, a 5-HT1A receptor agonist (Fukumoto et al
15241 records 38/1017 page Previous Next First page 上5页 3637383940 下5页 Last page